Clinical Drug Experience Knowledgebase

alpha 1-Antitrypsin Deficiency (Phase 2)

Amyloid Neuropathies (Phase 3)

Amyloid Neuropathies, Familial (Phase 3)

Amyloidosis (Phase 3)

Amyloidosis, Familial (Phase 3)

Atypical Hemolytic Uremic Syndrome (Phase 2)

Azotemia (Phase 2)

Cardiomyopathies (Phase 3)

Communicable Diseases (Phase 2)

Coproporphyria, Hereditary (Phase 3)

Disease Progression (Phase 3)

Fatty Liver (Phase 1)

Glomerulonephritis (Phase 2)

Glomerulonephritis, IGA (Phase 2)

Hemoglobinuria (Phase 2)

Hemoglobinuria, Paroxysmal (Phase 2)

Hemolysis (Phase 2)

Hemolytic-Uremic Syndrome (Phase 2)

Hemophilia A (Phase 2)

Hemophilia B (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Hypercholesterolemia (Phase 1)

Hyperoxaluria, Primary (Phase 3)

Hypertension (Phase 1)

Infections (Phase 2)

Kidney Diseases (Phase 2)

Liver Diseases (Phase 2)

Neoplasms (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 1)

Polyneuropathies (Phase 3)

Porphyria, Acute Intermittent (Phase 3)

Porphyria, Erythropoietic (Phase 3)

Porphyrias (Phase 3)

Porphyrias, Hepatic (Phase 3)

Porphyria, Variegate (Phase 3)

Respiratory Syncytial Virus Infections (Phase 2)

Syndrome (Phase 2)

Virus Diseases (Phase 2)